The reporting of serious adverse events or device deficiencies during interventional clinical performance studies and other performance studies involving risks for the subjects, and the reporting of serious incidents occurring after a device has been placed on the market should be clearly distinguished to avoid double reporting.
Chun tuairisciú dubáilte a sheachaint, ba cheart idirdhealú soiléir a bheith idir, ar thaobh amháin, tuairisciú tarluithe díobhálacha tromchúiseacha nó easpaí ar fheistí le linn staidéir idirghabhálacha ar fheidhmíocht chliniciúil agus le linn staidéir eile feidhmíochta lena mbaineann rioscaí do na hábhair agus, ar an taobh eile, tuairisciú teagmhas tromhchúiseach a tharlaíonn tar éis feiste leighis a chur ar an margadh.